Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Deloitte
US Army
Julphar
Healthtrust
UBS
Dow
Colorcon

Generated: July 15, 2018

DrugPatentWatch Database Preview

Nandrolone decanoate - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for nandrolone decanoate and what is the scope of nandrolone decanoate patent protection?

Nandrolone decanoate
is the generic ingredient in two branded drugs marketed by Aspen Global Inc, Abraxis Pharm, Akorn, Luitpold Pharms Inc, and Watson Labs, and is included in eleven NDAs. Additional information is available in the individual branded drug profile pages.

There are fifteen drug master file entries for nandrolone decanoate. One supplier is listed for this compound.
Pharmacology for nandrolone decanoate
Drug ClassAndrogen
Synonyms for nandrolone decanoate
(17-beta)-17-((1-Oxodecyl)oxy)estr-4-en-3-one
(17beta)-3-oxoestr-4-en-17-yl decanoate
(1S,2R,10R,11S,14S,15S)-15-methyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-14-yl decanoate
(1S,2R,10R,11S,14S,15S)-15-methyl-5-oxotetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadec-6-en-14-yl decanoate
(1S,2R,10R,11S,14S,15S)-15-METHYL-5-OXOTETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADEC-6-EN-14-YL DECANOATE
(8R,9S,10R,13S,14S,17S)-13-Methyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl decanoate
[(8R,9S,10R,13S,14S,17S)-13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] decanoate
17-beta-Hydroxyestr-4-en-3-one decanoate
17b-[(1-oxodecyl)oxy]estr-4-en-3-one
17BETA-HYDROXY-19-NOR-4-ANDROSTEN-3-ONE 17-DECANOATE
17BETA-HYDROXY-4-ESTREN-3-ONE 17-DECANOATE
17beta-Hydroxyestr-4-en-3-one 17-decanoate
17beta-Hydroxyestr-4-en-3-one decanoate
17BETA-NANDROLONE DECANOATE
19-nor-4-androstene-17 beta-ol-3-one 17-decanoate
19-Norandrostenolone decanoate
19-NORTESTOSTERONE 17-DECANOATE
19-Nortestosterone decanoate
19-Nortestosterone-17.beta.-decanoate
19-Nortestoteronedecanoate
360-70-3
360N703
4-ESTREN-17BETA-OL-3-ONE 17-DECANOATE
4-ESTREN-17BETA-OL-3-ONE DECANOATE
AB03760
AC-1484
AC1L1TKM
Adenocorin
AK309978
AKOS025311438
AN-14913
Anabolin Depot
Anaboline Depot
Axedanin
BRN 2228051
C-22219
C08154
CAS-360-70-3
CC-32424
CHEBI:7467
CHEMBL1200946
CS-4613
CTK8D6788
D00955
DB08804
Deca Durabolin
Deca-Durabol
Deca-Durabolin
Deca-Durabolin (TN)
Deca-Durobolin
Deca-Hybolin
Decadurabolin
Decadurobolin
DECANOIC ACID 13-METHYL-3-OXO-2,3,6,7,8,9,10,11,12,13,14,15,16,17-TETRADECAHYDRO-1H-CYCLOPENTA[A]PHE
Dimapolan
DRG 0264
DSSTox_CID_3352
DSSTox_GSID_23352
DSSTox_RID_76988
DTXSID7023352
EINECS 206-639-3
Estr-4-en-3-one, 17-((1-oxodecyl)oxy)-, (17beta)-
Estr-4-en-3-one, 17-[(1-oxodecyl)oxy]-, (17.beta.)-
Estr-4-en-3-one, 17-[(1-oxodecyl)oxy]-, (17b)-
Estr-4-en-3-one, 17-beta-hydroxy-, decanoate
GS-3155
H45187T098
HY-13698
Hybolin decanoate
JKWKMORAXJQQSR-MOPIKTETSA-N
LP086471
LS-64854
LT01138619
MFCD00135100
MolPort-006-111-246
naboline
Nandrobolic L.A
Nandrolone 17beta-decanoate
Nandrolone decanoate (JAN/USP)
Nandrolone decanoate [USAN:JAN]
Nandrolone decanoate for peak identification, European Pharmacopoeia (EP) Reference Standard
Nandrolone decanoate for system suitability, European Pharmacopoeia (EP) Reference Standard
Nandrolone decanoate, European Pharmacopoeia (EP) Reference Standard
Nandrolone decanoate, United States Pharmacopeia (USP) Reference Standard
NCGC00159403-02
NCGC00159403-04
NCGC00263561-01
ndrolone-D
Norandrostenolone decanoate
Nortestosterone decanoate
Palactin
PL000379
Retabolil
Retabolyl
Rougerol
Salistoperm
SCHEMBL27975
Superbolan
Tox21_111638
Tox21_111638_1
UNII-H45187T098
ZINC8214619
Ziremilon

US Patents and Regulatory Information for nandrolone decanoate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Watson Labs NANDROLONE DECANOATE nandrolone decanoate INJECTABLE;INJECTION 087599-001 Oct 6, 1983 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Abraxis Pharm NANDROLONE DECANOATE nandrolone decanoate INJECTABLE;INJECTION 088290-001 Oct 3, 1983 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Watson Labs NANDROLONE DECANOATE nandrolone decanoate INJECTABLE;INJECTION 086385-001 Jan 13, 1984 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Watson Labs NANDROLONE DECANOATE nandrolone decanoate INJECTABLE;INJECTION 087598-001 Oct 6, 1983 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Daiichi Sankyo
Boehringer Ingelheim
Covington
Cipla
Johnson and Johnson
Mallinckrodt
QuintilesIMS
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.